OM
Outset Medical, Inc.
There isn't enough reported data to score OM yet.
OM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
OM's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OM PE Valuation
OM has no meaningful PE right now: it lost money over the past year.
OM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect OM's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2022 | -$51.45 | -$10.05 |
| Q2 2022 | -$48.45 | +$34.80 |
OM is still losing money, but less than at its worst: $51.45 per share over the past year, against $83.25 at its worst in mid-2021.
OM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $33.6M | +14% |
| Q2 2026 | $31.6M | +0.7% |
| Q1 2026 | $27.9M | -6.3% |
| Q4 2025 | $28.9M | -2% |
| Q3 2025 | $29.4M | +2.7% |
| Q2 2025 | $31.4M | +15% |
| Q1 2025 | $29.8M | +5.6% |
| Q4 2024 | $29.5M | -3.4% |
OM's revenue grew through 2023 and has held roughly level since: $34M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -37% | +17 points |
| Q2 2026 | -50% | +4.1 points |
| Q1 2026 | -61% | -5.6 points |
| Q4 2025 | -61% | +13 points |
| Q3 2025 | -54% | +29 points |
| Q2 2025 | -54% | +59 points |
| Q1 2025 | -55% | +76 points |
| Q4 2024 | -74% | +48 points |
OM's operating margin was −37% last quarter, up 17 points from the same quarter a year ago, near the top of its range since 2019.
OM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.5M | -$4M |
| Q2 2026 | -$9.7M | -$4.6M |
| Q1 2026 | -$12.9M | +$12.9M |
| Q4 2025 | -$9.7M | +$6.8M |
| Q3 2025 | -$6.5M | +$14.5M |
| Q2 2025 | -$5.1M | +$28.3M |
| Q1 2025 | -$25.8M | +$20.5M |
| Q4 2024 | -$16.5M | +$9M |
OM has burned cash in almost every quarter: −$43M over the past year, against −$54M the year before.
OM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.1% | -66.6K shares |
| 1 year | +271% | +2.2M shares |
OM has 3M diluted shares, up 271% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
OM Net Leverage
OM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.3 | Neutral |
| Stochastic | 49.2 | Neutral |
OM's weekly RSI is 45 (neutral) and its Stochastic is 49 (neutral).
OM PE vs Healthcare Sector
OM has no meaningful PE right now: it lost money over the past year.
OM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.90 | 1% below |
| 20 week MA | $4.03 | 4.2% below |
| 50 week MA | $4.10 | 5.9% below |
| 100 week MA | $9.02 | 57% below |
| 200 week MA | $73.2 | 95% below |
OM is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
OM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $900.2 | $798.9 | -11% |
| 2021 | $798.9 | $681.2 | -15% |
| 2022 | $681.2 | $378.8 | -44% |
| 2023 | $378.8 | $81.2 | -79% |
| 2024 | $81.2 | $17.1 | -79% |
| 2025 | $17.1 | $3.36 | -80% |
| 2026 YTD | $3.36 | $3.86 | +15% |
OM has finished every year since 2020 lower, and it's up 15% so far in 2026.